2016
Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition
Shi X, Sousa LP, Mandel-Bausch EM, Tome F, Reshetnyak AV, Hadari Y, Schlessinger J, Lax I. Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: e4784-e4793. PMID: 27482095, PMCID: PMC4995958, DOI: 10.1073/pnas.1610179113.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalCell ProliferationHumansMiceMutationNeoplasmsNIH 3T3 CellsPrecision MedicineProtein Kinase InhibitorsProto-Oncogene Proteins c-kitConceptsTyrosine kinase inhibitorsCombination of TKIsAnti-Kit antibodiesKIT mutantsPrecision medicine treatmentAntibody treatmentMedicine treatmentLow dosePrecision medicine effortsToxin conjugatesKIT inhibitorsActivating mutationsDistinct cellular propertiesReceptor tyrosine kinasesKinase inhibitorsCell inhibitionCancer cellsGenomic sequencing analysisCancer cell inhibitionMedicine effortsCancerTreatmentTyrosine kinaseSequencing analysisInhibitors
2013
Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region
Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, Tome F, Suzuki Y, Sidhu SS, Lax I, Schlessinger J. Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 17832-17837. PMID: 24127596, PMCID: PMC3816449, DOI: 10.1073/pnas.1317118110.Peer-Reviewed Original ResearchConceptsKIT antibodyReceptor tyrosine kinase inhibitionGastrointestinal stromal tumorsAcute myeloid leukemiaDurable disease controlTyrosine kinase inhibitorsTyrosine kinase inhibitionSomatic oncogenic mutationsUnique therapeutic approachClinical progressionStromal tumorsMyeloid leukemiaTherapeutic approachesDramatic responseTreatment of KITDrug resistanceDisease controlIsolated antibodyKIT inhibitionKinase inhibitorsAntibodiesCancerCell proliferationOncogenic mutationsKinase inhibition